Publication:
What to expect from HER-2 directed therapies in advanced gastric cancer?

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsDane, Faysal
dc.date.accessioned2022-03-10T11:39:29Z
dc.date.accessioned2026-01-10T21:29:35Z
dc.date.available2022-03-10T11:39:29Z
dc.date.issued2015-04-15
dc.description.abstractGastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.
dc.identifier.doi10.5472/mmj.87204
dc.identifier.issn1309-9469
dc.identifier.urihttps://hdl.handle.net/11424/219872
dc.identifier.wosWOS:000430063900003
dc.language.isoeng
dc.publisherMARMARA UNIV, FAC MEDICINE
dc.relation.ispartofMARMARA MEDICAL JOURNAL
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGastric cancer
dc.subjectHER-2/neu
dc.subjectTargeted therapy
dc.titleWhat to expect from HER-2 directed therapies in advanced gastric cancer?
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage15
oaire.citation.issue4
oaire.citation.startPage11
oaire.citation.titleMARMARA MEDICAL JOURNAL
oaire.citation.volume28

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
188.06 KB
Format:
Adobe Portable Document Format
Download

Collections

Araştırma Çıktıları